All News
#OP0225 at #EULAR2026: In this nationwide French cohort, patients with IMIDs had nearly 2x risk of HPV-related cancers or severe dysplasia versus matched controls. Risk was particularly increased in SLE, reinforcing the importance of HPV vaccination and screening. @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 OP0228 Is there “something in the air?” Data from US Market Scan: poor quality index was associated with increased risk of #SLE. Although causal inference cannot be deduced, seems an important environmental factor. To check air quality assoc with UV index @RheumNow https://t.co/1FOw7RDA9a
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Which ‘CAR’ to drive in #SLE?
Comparison of #CD19 #CAR-T
#allogenic vs #Autologous
➡️ comparing #molecular #responses from 2 #lupus studies N=12
Both improved cytokine signatures
For
#IFN & #neutrophils
Results similar not identical
?either
#POS0678 #EULAR2026 @RheumNow https://t.co/Lcpv3qJ6tU
Links:
Janet Pope Janetbirdope ( View Tweet)
Rheumatology Shortage Cliff in Australia & USA
Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States. The Australian Rheumatology Association's 2025 Workforce Report warns that the nation faces a significant https://t.co/qVziLM25JR
Dr. John Cush RheumNow ( View Tweet)
#OP0224 at #EULAR2026: Poor air quality may contribute to lupus risk. In a cohort of 8.3 million people, higher AQI exposure and more unhealthy air quality days were associated with increased incident SLE. Adds to evidence linking environmental exposures & autoimmunity. @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
JAKi vs TNFi in #RA: Swedish registry (n=21,314) shows JAKi carries ↑ risk of hospitalized infections (IRR 1.23) and ~2x viral infection risk after accounting for treatment discontinuation. Treatment selection matters. @RheumNow #EULAR2026 POS0070
Jiha Lee JihaRheum ( View Tweet)
Do we really need yet another JAKi?
COURAGE-RA RCT phIII JAK1-selective Zemprocitinib RA bDMARDs IR
Primary endpoint ACR20 at wk24
79.1% vs 39.7% PBO (p<0.0001)
wk24 ACR50: 55.8% vs 22.0%
wk 24 DAS28-CRP ≤3.2: 67.0% vs 23.4%
No new safety signal
Looks very similar to other https://t.co/b0RMBWl4Xx
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Low-dose blinatumomab in multidrug-resistant RA
15 pts 96h cycles CD3×CD19 T-cell engager
DAS28-CRP: 4.8 → 2.4
3 mo ACR20 100% ACR50 73% ACR70 53%
DAS28 remission 33%
But... only transient efficacy with
93% relapse after stopping treatment
Authors highlight response to https://t.co/GCS6774tJt
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2026 OP0221 Can we refine response measure in #lupusnephritis RCT? Asia Pacific cohort: construct validity of TRM-SLE definition: 1)RCT entry threshold uPCR >1g/g; 2)clinically meaningful response >50% improvement in UPCR; 3)stricter complete response UPCR<0.2g/g @RheumNow https://t.co/dlErgyFMZP
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#OP0223 at #EULAR2026: Not every lupus nephritis patient may need upfront triple therapy. Using EULAR 2025 prognostic factors, triple therapy significantly improved complete renal response only in high-risk patients, supporting more precision-based treatment approach. @RheumNow https://t.co/F8Kn23YjNr
Mrinalini Dey DrMiniDey ( View Tweet)
Ivarmacitinib (selective oral JAKi) in active nr-axSpA:
This ph3 RCT showed that Ivarmacitinib 4mg significantly improved s/sxs & dse act vs. PBO at wk 12 (39.7% vs 24.8%; P=0.0057) and maintained until wk 24
Interesting. A new JAKi option for axSpA
OPO237 @RheumNow #EULAR2026 https://t.co/bxbO8GfegP
Links:
sheila RHEUMarampa ( View Tweet)
#OP0222 at #EULAR2026: ReBioLup highlights the disconnect between proteinuria & histopathological activity in lupus nephritis. 73% of patients with persistent histologic activity at 12 months still met criteria for complete clinical response. @RheumNow https://t.co/VxgT6812VO
Mrinalini Dey DrMiniDey ( View Tweet)
ASAS-SPARTAN revised #axSpA classification criteria have hug specificity (>94%) but lower sensitivity than the 2009 criteria, excluding ~27% of patients classified by the older criteria Abstr OP239 @RheumNow #EULAR2026 https://t.co/vGJN8eEKKh
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK1 inhibition achieves near-remission rates above placebo. An oral option for early axSpA Abstr#0241 @RheumNow #EUlAR2026
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#OP0219 at #EULAR2026: Real-world ASTER data suggest DORIS remission & LLDAS are achievable with anifrolumab in routine practice, assoc w ⬇️risk of organ damage accrual. Over 12m, 43% attained DORIS remission & 74% LLDAS. Low serious adverse event rates reported. @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 OP0216 With the advances in biologics/cell-based therapies in #SLE, we need to define “severe refractory.” Data-driven analysis from 13 nations suggested: SLEDAI≥6 + PGA>1 + mild-moderate or severe flare (MMSf) + GC≥10 +IS. Need validation study before use @RheumNow https://t.co/K2dMSQUIgB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#OP006 - Urine proteomics in LN tracks histo activity & treatment response better than proteinuria. Paired biopsies linked active disease to IFNI, IL12, complement & neut pathways- normalised in responders but persisted in non-responders. @RheumNow #EULAR2026 #EULARBest #Plenary
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 Please find my video interview with Prof Xavier Mariette, the presenting author of Abstract OP0126: Efficacy and Safety of Ianalumab in #Sjogren disease #SjD @RheumNow
https://t.co/NEyBOD6Qj2 https://t.co/Zn1fH6eu39
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
💉 Is Izokibep (Novel IL-17i) durable in PsA at 1yr?
Phase2b/3 RCT: ~50% ACR50 at week in 343pts
OP073 #EULAR2026 @RheumNow https://t.co/M3nrKFTA7c
Nelly ZIADE 🍀 Nellziade ( View Tweet)
